Related Experiment Video
Updated: Mar 19, 2026
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasis
Russell Maxwell1, Tomas Garzon-Muvdi1, Evan J Lipson2
1Department of Neurosurgery, Johns Hopkins Medical Institutes, Baltimore, MD.
Abstract:
Brain metastasis is common and carries a poor prognosis in melanoma. A single institution, retrospective cohort of 225 melanoma patients was analyzed to determine if BRAF-V600 mutational status was associated with brain metastasis. Eighty-three of the 225 patients (37%) had BRAF-V600 mutations. At initial diagnosis, BRAF-V600 mutations were associated with younger age (p ≤ 0.001), higher proportion of females (p = 0.0037), higher AJCC stage (p = 0.030), regional lymph node involvement (p = 0.047), and family history of cancer (p = 0.044). Compared to BRAF-WT, BRAF-V600 patients had an increased risk of brain metastasis in multivariate analysis (OR = 2.24; 95% CL = 1.10-4.58; p = 0.027). However, BRAF-V600 patients treated with a selective BRAF inhibitor (BRAFi) had a similar risk of brain metastasis compared to BRAF-WT patients (OR = 1.00; 95% CL = 0.37-2.65; p = 0.98). Moreover, treatment with BRAFi significantly prolonged the time from initial diagnosis to brain metastasis diagnosis (HR = 0.30; 95% CL = 0.11-0.79; p = 0.015). Compared to other tissues, the brain was the most frequent site of metastasis in BRAF-V600 patients without BRAFi (42% ± 7%). The frequency of brain metastasis was lower in BRAF-WT and BRAF-V600 patients with BRAFi (25% ± 4% and 25% ± 8%, respectively). The proportion of patients with brain metastasis as the only site was 40%, 60%, and 0% in the BRAF-WT, BRAF-V600 without BRAFi, and BRAF-V600 with BRAFi groups, respectively. This study provides evidence on the clinical importance of BRAF-V600 mutations and BRAF inhibition in the progression to melanoma brain metastasis.
Insights
BRAF-V600 mutations increase melanoma brain metastasis risk. However, BRAF inhibitors significantly reduce this risk and delay metastasis, showing their clinical importance.
Area of Science:
- Oncology
- Genetics
- Dermatology
Background:
- Brain metastasis is a frequent and severe complication in melanoma patients.
- BRAF-V600 mutations are common in melanoma and influence disease characteristics.
Purpose of the Study:
- To investigate the association between BRAF-V600 mutational status and the development of brain metastasis in melanoma.
- To evaluate the impact of BRAF inhibitors (BRAFi) on brain metastasis in BRAF-V600 mutated melanoma patients.
Main Methods:
- Retrospective analysis of 225 melanoma patients.
- Assessment of BRAF-V600 mutation status.
- Multivariate analysis to determine risk factors for brain metastasis.
- Comparison of brain metastasis incidence and timing between BRAF-V600 mutated patients with and without BRAFi treatment, and BRAF-wildtype patients.
Main Results:
- BRAF-V600 mutations were associated with younger age, female sex, higher AJCC stage, lymph node involvement, and family history.
- BRAF-V600 mutated patients had a significantly increased risk of brain metastasis compared to BRAF-wildtype (WT) patients (OR=2.24).
- Treatment with BRAF inhibitors (BRAFi) normalized the risk of brain metastasis in BRAF-V600 patients (OR=1.00) and significantly prolonged the time to metastasis (HR=0.30).
- The brain was the most frequent site of metastasis in BRAF-V600 patients without BRAFi (42%).
- BRAFi treatment reduced brain metastasis frequency to 25% in both BRAF-V600 and BRAF-WT patients.
Conclusions:
- BRAF-V600 mutation status is a significant predictor of brain metastasis in melanoma.
- Selective BRAF inhibitors are crucial in mitigating the risk and delaying the onset of brain metastasis in BRAF-V600 mutated melanoma.
- BRAFi therapy demonstrates substantial clinical benefit in managing melanoma brain metastasis.
